Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? - Wikidata - wikimedia - TriplyDB

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

http://www.wikidata.org/entity/Q44355177

about

The role of the arginine metabolome in pain: implications for sickle cell disease Arginase and pulmonary diseases Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia Developmental changes in arginase expression and activity in the lung Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia.Pulmonary complications of sickle cell disease.Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria.Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.Alterations in lung arginine metabolism in lambs with pulmonary hypertension associated with increased pulmonary blood flow Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients.Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.Acute chest syndrome: sickle cell disease.Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.Amino acids, arginase and nitric oxide in vascular health.Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.Protective effect of arginine on oxidative stress in transgenic sickle mouse models.Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.The Role of Nutrition in Sickle Cell Disease.Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions Vasculopathy and pulmonary hypertension in sickle cell disease.Pharmacotherapy in sickle cell disease--state of the art and future prospects Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?Effects of a single sickling event on the mechanical fragility of sickle cell trait erythrocytes Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003.Body composition and grip strength are improved in transgenic sickle mice fed a high-protein diet Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease.Redox-dependent impairment of vascular function in sickle cell disease.An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice.Arginine metabolism in vascular biology and disease.Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.Cerebrovascular disease associated with sickle cell pulmonary hypertension.Update in pulmonary hypertension 2005.Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.Arginine de novo and nitric oxide production in disease states.Therapeutic use of citrulline in cardiovascular disease.

P2860

Q26751338-7BD93145-F5D7-499D-99A6-97364BAFF24F Q28385094-2BE2B40E-7C4A-491D-A323-8FABB62467A6 Q28395387-4A8740A0-7DF8-414B-9A0B-AFCFCB745BFA Q28579809-6C5937B0-C8D5-4FE5-B731-8C03D46ACC04 Q30275352-98D52AEE-4B8D-4C47-9B51-94F5258F5068 Q30515769-65B79552-E683-4DBF-8D44-01021E75A732 Q33303521-41A754FC-CFE0-4A40-8314-86C8149DF977 Q33803027-AB31BA48-F7C6-4660-87CE-77F3FF97C226 Q33889591-495A6924-7500-4A13-9F60-9B091AC8D757 Q33899415-8FC102CC-71C3-4626-B483-228AA0D6E1B7 Q34013495-AB4F06AC-01DF-47E5-AB4D-AD1A87E36B5D Q34038886-1B42E931-0094-40A8-B5AA-6331019A81F2 Q34187526-D2887455-386C-4D19-AE3A-F4FB85C08E38 Q34431518-5421F67D-4668-49C5-BD63-9C625BC07B36 Q34436782-50021729-25E7-4987-9596-382A52CF1C67 Q34489450-188961D1-4F8B-4730-963B-05E4F2E92EF6 Q34579250-2DC263D8-44FE-4F4E-AAA1-A97568C8610D Q34589136-FE1DAFA2-A454-4A1A-A225-9681D8362B3A Q34775883-F6C4AF25-E31B-4EC0-9471-C0EB4F5A211C Q34891505-2585E1D3-8B14-4C35-8D6D-C821ABB00D63 Q34898802-61FC89F7-D54C-45F8-B48A-BE28A8A8A186 Q34992760-8FE992F0-DD04-4ED6-A149-CFBDC993C7B5 Q35086394-9D6C8641-A3FC-41EE-867A-4BE77B527A51 Q35220342-9FDCF5E5-0D2F-4B75-83E7-92ABA7679A63 Q35339312-BBAD5599-2192-4C6E-B065-296E904CD1C5 Q35580607-FC1BE06B-D74E-4DB0-BC54-8C45F68BCBC2 Q35590733-45554FCD-2F7F-43D1-BBBE-1FF354813623 Q35626624-BCD3C1B7-2BBF-4F9B-984F-781FD038F0FC Q35668179-745C6F5F-E845-4C2C-A187-8A4759EE599F Q35849493-C2494007-64EE-4013-9BB2-6ACF392AD3EA Q36088594-719F3EEE-5BBE-4CAE-BB48-8ACE40FDD969 Q36274222-81823C42-5D7C-4CC6-943A-9B38300261EA Q36328854-1A70A568-BF43-4E34-8E70-559ED05C8F2A Q36381021-563F8AB8-AB01-4FAF-9328-F27140833244 Q36384658-9906F019-B9CF-408B-B119-C684DE149F1B Q36392798-839FFDE6-03E9-4C8F-8B62-976F80D644D3 Q36403168-41D8E444-4995-40D1-AE91-F39BBE3CF670 Q36419650-82FA76CD-0067-4F63-B3BA-84C9D7FBE6A5 Q36454194-EBA87C54-A6D6-4B96-B1BA-2D23EE253346 Q36703841-A65703FE-5E2D-4946-8FA2-C884BAF0A293

P2860

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

http://www.wikidata.org/entity/Q44355177

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@en

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@nl

type

label

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@en

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@nl

prefLabel

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@en

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@nl

P1433

Q44355177-715418AB-1092-4E00-994A-618A0ED60F20

P1476

Q44355177-4250C574-03A9-4B06-8836-4E750252163D

P2093

Q44355177-0EDE197C-D7A0-4C8E-8B0D-108452150844

Q44355177-2F445801-5CAA-4DF9-A33E-5E9E172B2946

Q44355177-36B60F96-5266-463F-A310-64EE8ED10877

Q44355177-524F2075-4A6A-4B9C-908A-8952B05C13A3

Q44355177-5F0456EA-E44E-43DF-AB21-34F09AAC4E78

Q44355177-67F3A09B-0806-4962-B335-567955AD8634

Q44355177-80B651EE-06EF-4941-BFA0-19A3085EDABE

Q44355177-FC562780-5F96-4402-9B4C-B1FDE4C73F88

P2860

Q44355177-0C019CB0-4F00-4FCE-968B-A46A6605EDEE

Q44355177-1EDC5EC6-B5E2-4457-A056-A79EA9F0F28A

Q44355177-23901CBD-8545-4B50-AAE1-8BEBE31B168C

Q44355177-23A63CD0-A44A-4C8E-A9A9-F2A9A3E63D02

Q44355177-315DAB89-B0A5-4B37-A332-DF435D823347

Q44355177-39BC6250-34F2-4FED-A1D2-C117C08FB37E

Q44355177-43E025A1-477D-4B36-8128-49681431F3EC

Q44355177-490C69F2-A3D3-4977-A3FA-55B524F59C02

Q44355177-49803ECD-5E0A-4477-AB5B-8BEA176A1093

Q44355177-58027CF3-E12E-44FE-A1A4-D5BD214DA114

P304

Q44355177-E4C99171-3ABC-46BC-A757-D5A7223AB722

P31

Q44355177-972E0381-C025-41F3-9FC2-B3F791F2FA4A

P356

Q44355177-E5CD57CB-4AB6-4B44-9463-754E31BB5C9F

P407

Q44355177-DF0A73AB-04D3-486E-B7D3-3DE9C8C43B14

P433

Q44355177-430CE16B-F505-449D-AABD-9C279FE7ACFE

P478

Q44355177-F7EFA270-D49F-4A86-AC2F-98B73474F9A5

P50

Q44355177-D8026B98-8369-458B-A8CD-3D2124028A06

P577

Q44355177-80E81A16-B8C2-4DD9-9597-9D5C4DF5615F

P698

Q44355177-E37FAE4D-C136-4F71-BDD5-DBD7E0DEA8DD

P356

RCCM.200208-967OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

@en

P2093

Claudia R Morris

http://www.w3.org/2001/XMLSchema#string

Diane Kepka-Lenhart

http://www.w3.org/2001/XMLSchema#string

Frans A Kuypers

http://www.w3.org/2001/XMLSchema#string

Jane Van Warmerdam

http://www.w3.org/2001/XMLSchema#string

Lorenzo Machado

http://www.w3.org/2001/XMLSchema#string

Sidney M Morris

http://www.w3.org/2001/XMLSchema#string

Susan Claster

http://www.w3.org/2001/XMLSchema#string

Ward Hagar

http://www.w3.org/2001/XMLSchema#string

P2860

The L-arginine-nitric oxide pathway

Arginine metabolism: nitric oxide and beyond

Regulation of enzymes of the urea cycle and arginine metabolism

Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure

The transport activity of the human cationic amino acid transporter hCAT-1 is downregulated by activation of protein kinase C

Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies.

Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization.

Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.

Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity.

Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

P304

63-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200208-967OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P50

Elliott Vichinsky

P577

2003-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12626350

http://www.w3.org/2001/XMLSchema#string